The UK's controversial drug pricing deal with the US has sparked a legal battle, with campaigners threatening to take the government to court. The deal, which grants the health secretary the power to override the National Institute for Health and Care Excellence (NICE) in determining drug prices, has been met with fierce opposition. The campaign groups Global Justice Now and Just Treatment argue that this move constitutes an 'unlawful power grab' and could lead to the NHS paying even higher prices for drugs. They have issued a stark warning to the Department of Health and Social Care, threatening a judicial review if the statutory instrument is not revoked.
The core issue here is the potential erosion of NICE's independence, a body revered for its impartiality. The government's agreement with the Trump administration, announced last December, could undermine this independence, allowing the health secretary to dictate prices for NHS-funded drugs. This shift has raised concerns among MPs from various parties, who have criticized the secrecy surrounding the deal and the government's reluctance to disclose its impact assessment.
Nick Dearden, director of Global Justice Now, expresses his alarm, suggesting that the government is prioritizing geopolitical considerations over the well-being of NHS patients. He argues that this move risks sabotaging the existing mechanism for controlling drug prices, without proper parliamentary debate. The group's lawyers, Leigh Day, have sent a 'letter before claim' to the DHSC, highlighting the potential illegality of the statutory instrument.
The controversy extends beyond legal challenges, as it involves a fundamental question about the role of NICE and the government's responsibility to the NHS. The DHSC, however, maintains that NICE's independence will remain intact, emphasizing its role in providing guidance and recommendations free from political influence. They argue that this deal will facilitate access to innovative medicines, benefiting patients and ensuring tariff-free drug exports to the US for three years.
Despite the government's assurances, the legal and ethical implications of this deal are far-reaching. The campaigners' threat of a judicial review underscores the gravity of the situation, as it challenges the very foundation of NICE's independence. This case highlights the delicate balance between political interests and the healthcare needs of the public, leaving many questions unanswered and the future of the NHS in a state of uncertainty.
